JP5667060B2 - 乾癬を治療するための安定化組成物 - Google Patents
乾癬を治療するための安定化組成物 Download PDFInfo
- Publication number
- JP5667060B2 JP5667060B2 JP2011530054A JP2011530054A JP5667060B2 JP 5667060 B2 JP5667060 B2 JP 5667060B2 JP 2011530054 A JP2011530054 A JP 2011530054A JP 2011530054 A JP2011530054 A JP 2011530054A JP 5667060 B2 JP5667060 B2 JP 5667060B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight percent
- calcipotriene
- ddaip
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
乾癬は皮膚および関節を冒す非伝染性疾患である。この疾患には、乾癬プラークと呼ばれる、炎症および過剰皮膚産生の領域である皮膚上の落屑性赤斑(red scaly patches)が付随する。国立衛生研究所によると、750万人ものアメリカ人が乾癬を有している。乾癬を患う人々の約10パーセントから30パーセントが、関節痛、凝りおよび腫れを生じる、乾癬性関節炎として知られる関節疾患も発症するものと見積もられている。
本発明の貯蔵安定軟膏はビタミンD化合物、コルチコステロイドおよびN,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステル (C1−C4)−アルキル(C8−C22)カルボン酸エステルをワセリン担体中に含み、および、任意に、鉱油、トコフェロールまたはこの両者を含有する。好ましくは、ビタミンD化合物にはカルシポトリエンが含まれる。コルチコステロイドは、好ましくは、クロベタゾールの医薬的に許容し得る塩またはベタメタゾンの医薬的に許容し得る塩である。好ましいN,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステルはドデシル2−(N,N−ジメチルアミノ)−プロピオネート(DDAIP)である。
本発明は乾癬の治療に有用な貯蔵安定軟膏を提供する。本発明の組成物はビタミンD化合物、コルチコステロイドおよびN,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステル(C1−C4)−アルキル(C8−C22)カルボン酸エステルをワセリン(例えば、白色ワセリン)担体中に含み、並びに、任意に、鉱油、トコフェロール(ビタミンE)または鉱油およびトコフェロールの両者を含有する。
Claims (25)
- 乾癬の治療に適する貯蔵安定非水性軟膏組成物であって:
(a)ビタミンD化合物;
(b)コルチコステロイド;および
(c)N,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステル;
をワセリン担体中に含む組成物。 - さらに鉱油、トコフェロールまたは鉱油およびトコフェロールの組み合わせを含む、請求項1に記載の組成物。
- ビタミンD化合物がカルシポトリエンを含む、請求項1または2の組成物。
- コルチコステロイドが医薬的に許容し得るクロベタゾール塩および医薬的に許容し得るベタメタゾン塩からなる群より選択される、請求項1または2の組成物。
- N,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステルがドデシル2−(N,N−ジメチルアミノ)−プロピオネート(DDAIP)を含む、請求項1または2の組成物。
- ワセリン担体が白色ワセリンを含む、請求項1または2の組成物。
- ビタミンD化合物が組成物中に0.001から0.01重量パーセントの範囲の濃度で存在する、請求項1または2の組成物。
- コルチコステロイドが組成物中に0.01から0.1重量パーセントの範囲の濃度で存在する、請求項1または2の組成物。
- 組成物がトコフェロールを0.001から0.01重量パーセントの範囲の濃度で含む、請求項2の組成物。
- N,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステルが組成物中に0.1から5重量パーセントの範囲の濃度で存在する、請求項1または2の組成物。
- 組成物が1から10重量パーセントの鉱油を含む、請求項2の組成物。
- 乾癬の治療に適する貯蔵安定非水性軟膏組成物であって:
(a)0.001から0.01重量パーセントのビタミンD化合物;
(b)0.01から0.1重量パーセントのコルチコステロイド;
(c)0.001から0.01重量パーセントのトコフェロール;および
(d)0.1から5重量パーセントのN,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステル;
をワセリン担体中に含む組成物。 - さらに鉱油を含む、請求項12に記載の組成物。
- ビタミンD誘導体化合物がカルシポトリエンを含む、請求項12または13の組成物。
- コルチコステロイドがクロベタゾールプロピオネートおよびベタメタゾンジプロピオネートからなる群より選択される、請求項12または13の組成物。
- N,N−ジ(C1−C8)アルキルアミノ置換、(C4−C18)アルキル(C2−C18)カルボン酸エステルがドデシル2−(N,N−ジメチルアミノ)−プロピオネート(DDAIP)を含む、請求項12または13の組成物。
- ワセリン担体が白色ワセリンを含む、請求項12または13の組成物。
- 乾癬の治療に適する貯蔵安定非水性軟膏組成物であって:
(a)0.001から0.01重量パーセントのカルシポトリエン;
(b)0.01から0.1重量パーセントの、クロベタゾールプロピオネートおよびベタメタゾンジプロピオネートからなる群より選択されるコルチコステロイド;
(c)0.001から0.01重量パーセントのトコフェロール;および
(d)0.1から5重量パーセントのドデシル2−(N,N−ジメチルアミノ)−プロピオネート(DDAIP);
をワセリン担体中に含み、並びに約10重量パーセントまでの鉱油を含有する組成物。 - 組成物が約0.005重量パーセントのカルシポトリエンを含有する、請求項18の組成物。
- 組成物が約0.05重量パーセントのクロベタゾールプロピオネートを含有する、請求項18の組成物。
- 組成物が約0.064重量パーセントのベタメタゾンジプロピオネートを含有する、請求項18の組成物。
- 組成物が約1重量パーセントのDDAIPを含む、請求項18の組成物。
- 組成物が約0.002重量パーセントのトコフェロールを含む、請求項18の組成物。
- 組成物が約3重量パーセントの鉱油を含む、請求項18の組成物。
- ワセリン担体が白色ワセリンを含む、請求項18の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19512608P | 2008-10-03 | 2008-10-03 | |
US61/195,126 | 2008-10-03 | ||
PCT/US2009/005426 WO2010039251A1 (en) | 2008-10-03 | 2009-10-02 | Stabilized composition for treating psoriasis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012504607A JP2012504607A (ja) | 2012-02-23 |
JP5667060B2 true JP5667060B2 (ja) | 2015-02-12 |
Family
ID=42073781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011530054A Expired - Fee Related JP5667060B2 (ja) | 2008-10-03 | 2009-10-02 | 乾癬を治療するための安定化組成物 |
Country Status (18)
Country | Link |
---|---|
US (2) | US9220701B2 (ja) |
EP (1) | EP2343978A4 (ja) |
JP (1) | JP5667060B2 (ja) |
KR (1) | KR20110067145A (ja) |
CN (1) | CN102202509A (ja) |
AU (1) | AU2009300331A1 (ja) |
BR (1) | BRPI0920728A2 (ja) |
CA (1) | CA2739376A1 (ja) |
CL (1) | CL2011000722A1 (ja) |
CR (1) | CR20110225A (ja) |
EC (1) | ECSP11011022A (ja) |
IL (1) | IL212062A0 (ja) |
MX (1) | MX2011003568A (ja) |
NZ (1) | NZ592300A (ja) |
PE (1) | PE20110849A1 (ja) |
RU (1) | RU2526162C2 (ja) |
WO (1) | WO2010039251A1 (ja) |
ZA (1) | ZA201103061B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ592300A (en) * | 2008-10-03 | 2013-01-25 | Nexmed Holdings Inc | Stabilized composition for treating psoriasis |
US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
US8809307B2 (en) * | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
WO2014028780A2 (en) * | 2012-08-15 | 2014-02-20 | Nexmed Holdings, Inc. | Antifungal compounds and methods of use |
CN105784902A (zh) * | 2016-03-11 | 2016-07-20 | 重庆华邦制药有限公司 | 低浓度丁酸氯倍他松的检测方法 |
EP3456314A1 (en) | 2017-09-14 | 2019-03-20 | Tiofarma B.V. | Topical formulation comprising 17-ketolic corticosteroid |
US20210196631A1 (en) * | 2018-08-28 | 2021-07-01 | Glenmark Pharmaceuticals Limited | Container system and pharmaceutical foam composition comprising betamethasone |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980378A (en) * | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
US6046244A (en) | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
US6414028B1 (en) | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
TR200101790T2 (tr) | 1998-12-23 | 2001-10-22 | Idea Ag. | Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül |
HU230045B1 (hu) | 1999-04-23 | 2015-06-29 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Bőrgyógyászati alkalmazásra szolgáló nem vizes gyógyszerkészítmény |
JP2006511545A (ja) | 2002-12-17 | 2006-04-06 | ガルデルマ・ソシエテ・アノニム | カルシトリオール及びプロピオン酸クロベタゾールの組み合わせ物を含む医薬組成物 |
DK1635770T3 (da) * | 2003-03-21 | 2009-08-03 | Nexmed Holdings Inc | Antifungal neglelak og anvendelsesmetode |
US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
FR2871696B1 (fr) * | 2004-06-17 | 2006-11-10 | Galderma Sa | Composition topique pour le traitement du psoriasis |
US20060057075A1 (en) * | 2004-08-02 | 2006-03-16 | Moshe Arkin | Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof |
CA2633489C (en) * | 2005-12-14 | 2013-09-24 | Zars Pharma, Inc. | Compositions and methods for treating dermatological conditions |
US7560489B2 (en) | 2006-10-11 | 2009-07-14 | Nexmed Holdings, Inc. | Stabilized prostaglandin E composition |
NZ592300A (en) * | 2008-10-03 | 2013-01-25 | Nexmed Holdings Inc | Stabilized composition for treating psoriasis |
-
2009
- 2009-10-02 NZ NZ592300A patent/NZ592300A/xx not_active IP Right Cessation
- 2009-10-02 AU AU2009300331A patent/AU2009300331A1/en not_active Abandoned
- 2009-10-02 CN CN2009801396130A patent/CN102202509A/zh active Pending
- 2009-10-02 EP EP09818111.8A patent/EP2343978A4/en not_active Withdrawn
- 2009-10-02 JP JP2011530054A patent/JP5667060B2/ja not_active Expired - Fee Related
- 2009-10-02 CA CA2739376A patent/CA2739376A1/en not_active Abandoned
- 2009-10-02 PE PE2011000834A patent/PE20110849A1/es not_active Application Discontinuation
- 2009-10-02 RU RU2011117230/15A patent/RU2526162C2/ru not_active IP Right Cessation
- 2009-10-02 BR BRPI0920728-7A patent/BRPI0920728A2/pt not_active IP Right Cessation
- 2009-10-02 MX MX2011003568A patent/MX2011003568A/es active IP Right Grant
- 2009-10-02 KR KR1020117010072A patent/KR20110067145A/ko not_active Application Discontinuation
- 2009-10-02 WO PCT/US2009/005426 patent/WO2010039251A1/en active Application Filing
- 2009-10-02 US US12/998,261 patent/US9220701B2/en not_active Expired - Fee Related
-
2011
- 2011-03-31 IL IL212062A patent/IL212062A0/en unknown
- 2011-04-01 CL CL2011000722A patent/CL2011000722A1/es unknown
- 2011-04-21 ZA ZA2011/03061A patent/ZA201103061B/en unknown
- 2011-04-29 CR CR20110225A patent/CR20110225A/es unknown
- 2011-05-03 EC EC2011011022A patent/ECSP11011022A/es unknown
-
2015
- 2015-11-13 US US14/941,390 patent/US20160067266A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2011000722A1 (es) | 2012-01-20 |
ZA201103061B (en) | 2012-04-25 |
RU2011117230A (ru) | 2012-11-10 |
US20110237558A1 (en) | 2011-09-29 |
US9220701B2 (en) | 2015-12-29 |
CR20110225A (es) | 2011-07-18 |
KR20110067145A (ko) | 2011-06-21 |
NZ592300A (en) | 2013-01-25 |
ECSP11011022A (es) | 2011-06-30 |
BRPI0920728A2 (pt) | 2015-08-18 |
JP2012504607A (ja) | 2012-02-23 |
US20160067266A1 (en) | 2016-03-10 |
PE20110849A1 (es) | 2011-12-02 |
CN102202509A (zh) | 2011-09-28 |
AU2009300331A1 (en) | 2010-04-08 |
IL212062A0 (en) | 2011-06-30 |
RU2526162C2 (ru) | 2014-08-20 |
EP2343978A1 (en) | 2011-07-20 |
CA2739376A1 (en) | 2010-04-08 |
MX2011003568A (es) | 2011-06-09 |
EP2343978A4 (en) | 2013-11-27 |
WO2010039251A1 (en) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5667060B2 (ja) | 乾癬を治療するための安定化組成物 | |
CA2423930C (en) | Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid | |
EP2139452B1 (en) | Polyaphron topical composition with vitamin d and corticosteroid | |
AU2001291637A1 (en) | Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid | |
RU2003115616A (ru) | Композиции местного применения, содержащие, по меньшей мере, один витамин d или один аналог витамина d и, по меньшей мере, один кортикостероид | |
JP2004512297A5 (ja) | ||
JP2008297310A5 (ja) | ||
JP2008297309A5 (ja) | ||
CA2670425A1 (en) | Pharmaceutical compositions including vitamin d and corticosteroid | |
JP2016523960A (ja) | 限局性強皮症の膏薬療法 | |
JP2022185150A (ja) | ざ瘡の処置のためのカンナビノイドの製剤 | |
WO2015156219A1 (ja) | 抗真菌剤とステロイドとを含有する医薬組成物 | |
KR101755407B1 (ko) | 건선의 예방 또는 치료용 약제학적 조성물 | |
JP2000229884A (ja) | 皮膚外用剤 | |
JP6786252B2 (ja) | 皮膚用の医薬組成物 | |
JP5961062B2 (ja) | 皮膚外用剤組成物 | |
WO2023102363A1 (en) | Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers | |
JP2015205877A (ja) | 抗真菌剤とステロイド系薬剤とを含有する外用医薬組成物 | |
JP2000229852A (ja) | 皮膚外用剤 | |
JP2020055773A (ja) | 油性外用液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140414 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141014 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141017 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141211 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5667060 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |